There are
many forms
of CMT
disease,
including
CMT1, CMT2,
CMT3, CMT4,
and CMTX.
CMT1,
caused by
abnormalities
in the
myelin
sheath, has
three main
types.
CMT1A is
an autosomal
dominant
disease
resulting
from a
duplication
of the gene
on
chromosome
17 that
carries the
instructions
for
producing
the
peripheral
myelin
protein-22
(PMP-22).
The PMP-22
protein is a
critical
component of
the myelin
sheath. An
overabundance
of this gene
causes the
structure
and function
of the
myelin
sheath to be
abnormal.
Patients
experience
weakness and
atrophy of
the muscles
of the lower
legs
beginning in
adolescence;
later they
experience
hand
weakness and
sensory
loss.
Interestingly,
a different
neuropathy
distinct
from CMT1A
called
hereditary
neuropathy
with
predisposition
to pressure
palsy (HNPP)
is caused by
a deletion
of one of
the PMP-22
genes. In
this case,
abnormally
low levels
of the
PMP-22 gene
result in
episodic,
recurrent
demyelinating
neuropathy.
CMT1B
is an
autosomal
dominant
disease
caused by
mutations in
the gene
that carries
the
instructions
for
manufacturing
the myelin
protein zero
(P0), which
is another
critical
component of
the myelin
sheath. Most
of these
mutations
are point
mutations,
meaning a
mistake
occurs in
only one
letter of
the DNA
genetic
code. To
date,
scientists
have
identified
more than 30
different
point
mutations in
the P0 gene.
As a result
of
abnormalities
in P0, CMT1B
produces
symptoms
similar to
those found
in CMT1A.
The gene
defect that
causes
CMT1C, which
also has
symptoms
similar to
those found
in CMT1A,
has not yet
been
identified.
CMT2
results from
abnormalities
in the axon
of the
peripheral
nerve cell
rather than
the myelin
sheath.
There are
many
subtypes of
CMT2,
designated
by the
letters from
A-L. Each
subtype is
characterized
by the mode
of
inheritance
and
associated
clinical
features.
The genetic
loci have
been
identified
for some
subtypes.
Recently, a
mutation was
identified
in the gene
that codes
for the
kinesin
family
member
1B-beta
protein in
families
with CMT2A.
Kinesins are
proteins
that act as
motors to
help power
the
transport of
materials
along the
train tracks
(microtubules)
of the cell.
Another
recent
finding is a
mutation in
the
neurofilament-light
gene,
identified
in a Russian
family with
CMT2E.
Neurofilaments
are
structural
proteins
that help
maintain the
normal shape
of a cell.
CMT3
or
Dejerine-Sottas
disease
is a severe
demyelinating
neuropathy
that begins
in infancy.
Infants have
severe
muscle
atrophy,
weakness,
and sensory
problems.
This rare
disorder can
be caused by
a specific
point
mutation in
the P0 gene
or a point
mutation in
the PMP-22
gene.
CMT4
comprises
several
different
subtypes of
autosomal
recessive
demyelinating
motor and
sensory
neuropathies.
Each
neuropathy
subtype is
caused by a
different
genetic
mutation,
may affect a
particular
ethnic
population,
and produces
distinct
physiologic
or clinical
characteristics.
Patients
with CMT4
generally
develop
symptoms of
leg weakness
in childhood
and by
adolescence
they may not
be able to
walk. The
gene
abnormalities
responsible
for CMT4
have yet to
be
identified.
Please
proceed to
page two